Literature DB >> 1995950

Carboxy-terminally truncated dengue virus envelope glycoproteins expressed on the cell surface and secreted extracellularly exhibit increased immunogenicity in mice.

R H Men1, M Bray, C J Lai.   

Abstract

Recombinant vaccinia viruses expressing C-terminally truncated E's that ranged in length from 9 to 99% of the N-terminal sequence were constructed. The overall antigenicity of the E products was analyzed by radioimmunoprecipitation, using dengue virus hyperimmune mouse ascitic fluid (HMAF) or an anti-E peptide serum. Truncated E that was 79% or less in length did not bind HMAF efficiently, whereas E constructs greater than 79% were able to bind HMAF with high efficiency. The first 392 amino acids of the dengue type 4 virus E sequence, including the Arg-392 following the 79% E C terminus, appeared to be critical for proper antigenic structure required for efficient binding by HMAF. Truncated E's ranging from 59 to 81% in length were secreted extracellularly, whereas smaller or larger E's were retained intracellularly. Secreted E's contained carbohydrate side chains that were resistant to endoglycosidase H digestion, suggesting that the transport of E occurs via a pathway from the rough endoplasmic reticulum through the Golgi complex. 79% E-RKG (which possessed the three additional amino acids immediately downstream of 79% E) was expressed at a high concentration on the surface of recombinant virus-infected cells presumably being inserted into the plasma membrane by a hydrophobic C-terminal membrane anchor. Evaluation in mice of the protective efficacy of the various vaccinia virus E recombinants indicated that only truncated E's that were recognized efficiently by HMAF induced a high level of resistance to dengue virus encephalitis. 79% E-RKG which is expressed at a high concentration on the surface of infected cells was highly immunogenic when tested for induction of an E antibody response. This suggests that cell surface expression of 79% E-RKG was responsible for its enhanced immunogenicity. Finally, passive immunization studies indicated that serum antibodies to E played a major role in the complete or nearly complete resistance to dengue virus challenge induced by certain vaccinia virus-truncated E recombinants.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1995950      PMCID: PMC239918     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

Review 1.  Epitope mapping of flavivirus glycoproteins.

Authors:  F X Heinz
Journal:  Adv Virus Res       Date:  1986       Impact factor: 9.937

2.  Epitopic analysis of antigenic determinants on the surface of dengue-2 virions using monoclonal antibodies.

Authors:  E A Henchal; J M McCown; D S Burke; M C Seguin; W E Brandt
Journal:  Am J Trop Med Hyg       Date:  1985-01       Impact factor: 2.345

3.  Nucleotide sequence and deduced amino acid sequence of the structural proteins of dengue type 2 virus, Jamaica genotype.

Authors:  V Deubel; R M Kinney; D W Trent
Journal:  Virology       Date:  1986-12       Impact factor: 3.616

4.  Cloning full-length dengue type 4 viral DNA sequences: analysis of genes coding for structural proteins.

Authors:  B Zhao; E Mackow; A Buckler-White; L Markoff; R M Chanock; C J Lai; Y Makino
Journal:  Virology       Date:  1986-11       Impact factor: 3.616

5.  Studies on the nature of dengue viruses. IV. The structural proteins of type 2 dengue virus.

Authors:  V Stollar
Journal:  Virology       Date:  1969-11       Impact factor: 3.616

6.  Antigenic characterization of flavivirus structural proteins separated by isoelectric focusing.

Authors:  D W Trent
Journal:  J Virol       Date:  1977-06       Impact factor: 5.103

7.  Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution.

Authors:  C M Rice; E M Lenches; S R Eddy; S J Shin; R L Sheets; J H Strauss
Journal:  Science       Date:  1985-08-23       Impact factor: 47.728

8.  Anchoring a secreted plasmodium antigen on the surface of recombinant vaccinia virus-infected cells increases its immunogenicity.

Authors:  C J Langford; S J Edwards; G L Smith; G F Mitchell; B Moss; D J Kemp; R F Anders
Journal:  Mol Cell Biol       Date:  1986-09       Impact factor: 4.272

9.  Location of immunodominant antigenic determinants on fragments of the tick-borne encephalitis virus glycoprotein: evidence for two different mechanisms by which antibodies mediate neutralization and hemagglutination inhibition.

Authors:  F X Heinz; R Berger; W Tuma; C Kunz
Journal:  Virology       Date:  1983-10-30       Impact factor: 3.616

10.  Antigenic analysis of certain group B arthropodborne viruses by antibody absorption.

Authors:  D H CLARKE
Journal:  J Exp Med       Date:  1960-01-01       Impact factor: 14.307

View more
  20 in total

1.  Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses.

Authors:  A G Pletnev; M Bray; J Huggins; C J Lai
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

2.  Replication-defective adenoviral vaccine vector for the induction of immune responses to dengue virus type 2.

Authors:  Smita Jaiswal; Navin Khanna; S Swaminathan
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

3.  Recombinant dengue virus-like particles from Pichia pastoris: efficient production and immunological properties.

Authors:  Wenquan Liu; Hanning Jiang; Junmei Zhou; Xiaomeng Yang; Yunxia Tang; Danyun Fang; Lifang Jiang
Journal:  Virus Genes       Date:  2009-11-03       Impact factor: 2.332

4.  Synthesis and secretion of recombinant tick-borne encephalitis virus protein E in soluble and particulate form.

Authors:  S L Allison; K Stadler; C W Mandl; C Kunz; F X Heinz
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

5.  The length of and nonhydrophobic residues in the transmembrane domain of dengue virus envelope protein are critical for its retention and assembly in the endoplasmic reticulum.

Authors:  Szu-Chia Hsieh; Wen-Yang Tsai; Wei-Kung Wang
Journal:  J Virol       Date:  2010-02-24       Impact factor: 5.103

6.  Identification of chimpanzee Fab fragments by repertoire cloning and production of a full-length humanized immunoglobulin G1 antibody that is highly efficient for neutralization of dengue type 4 virus.

Authors:  Ruhe Men; Tetsu Yamashiro; Ana P Goncalvez; Claire Wernly; Darren J Schofield; Suzanne U Emerson; Robert H Purcell; Ching-Juh Lai
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

7.  Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo.

Authors:  Ana P Goncalvez; Cheng-Hsin Chien; Kamolchanok Tubthong; Inna Gorshkova; Carrie Roll; Olivia Donau; Peter Schuck; Sutee Yoksan; Sy-Dar Wang; Robert H Purcell; Ching-Juh Lai
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

8.  Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine.

Authors:  Jedhan U Galula; Wen-Fan Shen; Shih-Te Chuang; Gwong-Jen J Chang; Day-Yu Chao
Journal:  J Virol       Date:  2014-07-09       Impact factor: 5.103

9.  Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses.

Authors:  R Ralston; K Thudium; K Berger; C Kuo; B Gervase; J Hall; M Selby; G Kuo; M Houghton; Q L Choo
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

10.  Genetic determinants of dengue type 4 virus neurovirulence for mice.

Authors:  H Kawano; V Rostapshov; L Rosen; C J Lai
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.